Chimeric antigen receptor (CAR) T-cell therapyFDA-approvedInvestigational

Idecabtagene vicleucel

How it works

Redirects T-cells to recognize and kill cancer cells expressing BCMA, a protein found on multiple myeloma cells.

Cancer types

Leukemia— All patients

Efficacy

In clinical trials, around 80% of multiple myeloma patients achieved an objective response, with a median progression-free survival of approximately 11 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.